Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats

Journal of Hypertension

Volumn 30, Issue 9, 2012, Pages 1845-1855

  Takatsu, Miwa ^a   Hattori, Takuya ^a   Murase, Tamayo ^a   Ohtake, Masafumi ^a   Kato, Miki ^b   Nashima, Keigo ^b   Nakashima, Chieko ^b   Takahashi, Keiji ^a   Ito, Hiromi ^a   Niinuma, Kazumi ^c   Aritomi, Shizuka ^c   Murohara, Toyoaki ^a   Nagata, Kohzo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c AJINOMOTO CO INC   (Japan)

Author keywords

amlodipine; calcium channel blocker; cilnidipine; heart; hypertension; oxidative stress; remodeling

Indexed keywords

AMLODIPINE; CILNIDIPINE; MESSENGER RNA; NORADRENALIN; OSTEOPONTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDITIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84865446073     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283567645     Document Type: Article

References (54)

1. Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res 1999; 22:1-9. (Pubitemid 29192362)
2. Yamada T, Nagata K, Cheng XW, Obata K, Saka M, Miyachi M, et al. Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. Eur J Pharmacol 2009; 615:163-170.
3. Investigators TA. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
4. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46. (Pubitemid 36831120)
5. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca + +-channel antagonist, on N-type Ca + + channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997; 280:1184-1191. (Pubitemid 27166712)
6. Uneyama H, Uchida H, Konda T, Yoshimoto R, Akaike N. Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2 + channels. Eur J Pharmacol 1999; 373:93-100. (Pubitemid 29306714)
7. Rose GW, Kanno Y, Ikebukuro H, Kaneko M, Kaneko K, Kanno T, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24:377-383. (Pubitemid 32791814)
8. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27:379-385. (Pubitemid 38996928)
9. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72:1543-1549. (Pubitemid 350199443)
10. Varagic J, Susic D, Frohlich ED. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens 2002; 20:317-322. (Pubitemid 34913798)
11. Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002; 20:993-1000. (Pubitemid 34913681)
12. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005; 101:1-13.
13. Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006; 29:933-937.
14. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, Nitta K. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 2009; 30:155-161.
15. Takahara A, Konda T, Enomoto A, Kondo N. Neuroprotective effects of a dual L/N-type Ca(2 +) channel blocker cilnidipine in the rat focal brain ischemia model. Biol Pharm Bull 2004; 27:1388-1391. (Pubitemid 41701680)
16. Hayashi K, Kimata H, Obata K, Matsushita A, Fukata A, Hashimoto K, et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail 2008; 14:238-244. (Pubitemid 351434590)
17. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats. Evaluation of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during aging. Basic Res Cardiol 2003; 98:275-284. (Pubitemid 37107654)
18. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol 1995; 26:357-366. (Pubitemid 26011184)
19. Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K, et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008; 26:1669-1676.
20. Nagata K, Iwase M, Sobue T, Yokota M. Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure. J Am Coll Cardiol 1995; 25:295-304.
21. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002; 40:168-174. (Pubitemid 34840093)
22. Wang CT, Navar LG, Mitchell KD. Proximal tubular fluid angiotensin II levels in angiotensin II-induced hypertensive rats. J Hypertens 2003; 21:353-360. (Pubitemid 36269707)
23. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 2006; 7:74-86. (Pubitemid 44383501)
24. Ito K, Hirooka Y, Sunagawa K. Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. Circ Res 2009; 104:1004-1011.
25. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47:656-664. (Pubitemid 43740235)
26. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 2005; 45:283-287. (Pubitemid 40179973)
27. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16:2906-2912. (Pubitemid 44743488)
28. Li W, Knowlton D, Van Winkle DM, Habecker BA. Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons. Am J Physiol Heart Circ Physiol 2004; 286:H2229-H2236. (Pubitemid 38685237)
29. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, Nishizawa T, et al. Reduced myocardial sarcoplasmic reticulum Ca(2 +)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 2001; 104:658-663. (Pubitemid 32738519)
30. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109:2143-2149. (Pubitemid 38620225)
31. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46:719-724. (Pubitemid 43186744)
32. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schoneich C, Cohen RA. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004; 10:1200-1207. (Pubitemid 39540436)
33. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 2006; 24:1097-1104. (Pubitemid 43772318)
34. Fan YY, Kohno M, Nakano D, Ohsaki H, Kobori H, Suwarni D, et al. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens 2010; 28:1034-1043.
35. Lee YJ, Park KH, Park HH, Kim YJ, Lee KY, Kim SH, Koh SH. Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J Neurochem 2009; 111:90-100.
36. Uesawa Y, Mohri K. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. Yakugaku Zasshi 2008; 128:117-122.
37. Hishikawa K, Takase O, Idei M, Fujita T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76:230-231.
38. Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, et al. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. Free Radic Biol Med 2005; 38:616-630. (Pubitemid 40416858)
39. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 2003; 200:516-525. (Pubitemid 36818252)
40. Nishikawa N, Masuyama T, Yamamoto K, Sakata Y, Mano T, Miwa T, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 2001; 38:1539-1545. (Pubitemid 33033040)
41. Chen K, Chen J, Li D, Zhang X, Mehta JL. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPARgamma ligand pioglitazone. Hypertension 2004; 44:655-661. (Pubitemid 39435235)
42. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 2004; 43:739-745.
43. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43:499-503. (Pubitemid 38174161)
44. Takemori K, Ishida H, Dote K, Yamamoto K, Ito H. Prophylactic effects of an N-and L-type Ca2 + antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats. Can J Physiol Pharmacol 2005; 83:785-790. (Pubitemid 41784017)
45. Ferreira JC, Bacurau AV, Evangelista FS, Coelho MA, Oliveira EM, Casarini DE, et al. The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivityinduced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 2008; 294:R26-R32.
46. Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, et al. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 2010; 28:2156-2160.
47. Inoko M, Kihara Y, Sasayama S. Neurohumoral factors during transition from left ventricular hypertrophy to failure in Dahl salt-sensitive rats. Biochem Biophys Res Commun 1995; 206:814-820.
48. Delehanty JM, Himura Y, Elam H, Hood WB Jr, Liang CS. Betaadrenoceptor downregulation in pacing-induced heart failure is associated with increased interstitial NE content. Am J Physiol 1994; 266:H930-H935. (Pubitemid 24121310)
49. Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest 1985; 76:1740-1747. (Pubitemid 16196040)
50. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33:1447-1452. (Pubitemid 29282669)
51. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists. Fundam Clin Pharmacol 2004; 18:309-319. (Pubitemid 38758698)
52. Manabe I, Shindo T,Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91:1103-1113. (Pubitemid 36076358)
53. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, et al. Norepinephrine and concentric hypertrophy in patients with endstage renal disease. Hypertension 2002; 40:41-46. (Pubitemid 34755977)
54. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527-1539.